Hola,
Are you new here?

FAIR

financed

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREAT...

FLAGELLIN AEROSOL THERAPY AS AN IMMUNOMODULATORY ADJUNCT TO THE ANTIBIOTIC TREATMENT OF DRUG RESISTANT BACTERIAL PNEUMONIA Bacterial pneumonia is a leading cause of morbidity and mortality worldwide. Antibiotics constitute the standard of care but are faced with the emergence of antimicrobial resistance (AMR) and the curative failure. The FAIR consort... see more

30/06/2025

INSERM

10M€

Project Budget: 10M€

Project leader

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

PARTICIPATION DEPralty Sin fecha límite de participación.

Ver 16 Participantes

Financing granted El organismo H2020 notifico la concesión del proyecto The day 2019-12-06

SC1-BHC-14-2019: Stratified host-directed approaches... Specific Challenge:Despite major advances in development of new drugs and vaccines against infectiou...

I+D

Cerrada does 6 years

0% 100%

characteristics of the participant

Este proyecto no cuenta con búsquedas de partenariado abiertas en este momento.

Private Information

No hay información privada compartida para este proyecto. Habla con el coordinador.

16 Participantes

INSERM

3.16M€ | Leader

COMPAÑIA ESPAÑOLA DE PETROLE...

526.26K€ | participant

XTREMEDY MEDICAL

196.63K€ | participant

ERS

132.38K€ | participant

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Project duration: 66 months Date Start: 2019-12-06
End date: 2025-06-30

Project leader

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHER... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Project Budget 10M€

participation deadline Sin fecha límite de participación.

Project description Bacterial pneumonia is a leading cause of morbidity and mortality worldwide. Antibiotics constitute the standard of care but are faced with the emergence of antimicrobial resistance (AMR) and the curative failure. The FAIR consortium aims at assessing an adjunct to antibiotic therapy as an emerging concept of overcome AMR in pneumonia. The project leverages (i) a unique immunomodulatory flagellin that enhances airway epithelial innate immune defences and increases the therapeutic outcome relative to antibiotic alone, and (ii) airway-specific aerosol delivery by nebulization. FAIR’s objectives are to: • develop nebulization modalities for optimal airway targeting and rapid action at the infection site • demonstrate that nebulized flagellin strengthens the response to antibiotics in relevant preclinical models of antibiotic-resistant pneumonia • identify host immune factors required for the gain of protection with systems biology • implement pharmacokinetics/pharmacodynamics model-based design and simulation for clinical validation • assess nebulized flagellin’s safety in a Phase I clinical trial. • analyze the acceptability and economic relevance of the therapy • identify stratification markers that predict the course of pneumonia and treatment in antibiotic-treated cohorts. Expected outcomes include the enrichment of the pipeline of novel treatments against pneumonia, reinforcement of EU capacity to control AMR and infections, the Phase I safety report on nebulized flagellin, recommendations for future trials, and acceptability by the stakeholders and cost-effectiveness for public health. FAIR will develop new avenues of research on mechanisms of action of the adjunct flagellin, and will define (for future trials) the subpopulation of patients that might benefit most from this treatment. Our industrial partnerships and exploitation plan will enable straightforward development of drug and nebuliser device, and bring innovation to the patients.

Conecta tu I+D

Entra hoy

Forgot your password?

Financing

Companies

CTIs/Universidades

Projects

researchers